QTI571A2102E1 extension to imatinib PK study

• Research type

  Research Study

• Full title

  An open-label extension study to CQTI571A2102 to evaluate the long-term safety, tolerability and efficacy of QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension

• IRAS ID

  71741

• Contact name

  Gerry Coghlan

• Sponsor organisation

  Novartis Pharma Services AG

• Eudract number

  2010-021960-14

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  This is an open-label extension study to CQTI571A2102 to evaluate the long-term safety, tolerability and efficacy of QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension. The purpose of this extension study is to allow patients enrolled in CQTI571A2102 to continue the open label QTI571 treatment after completion of study CQTI571A2102 and to provide additional data on the long-term safety, tolerability, and efficacy of QTI571 in the treatment of severe pulmonary arterial hypertension.

• REC name

  South Central - Hampshire B Research Ethics Committee

• REC reference

  11/SC/0028

• Date of REC Opinion

  18 Apr 2011

• REC opinion

  Further Information Favourable Opinion